<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A few cases of secondary <z:hpo ids='HP_0002664'>neoplasms</z:hpo> occurring after treatment with 2-chloro-2'-<z:chebi fb="0" ids="16335">deoxyadenosine</z:chebi> (2CdA) have been reported, mostly in patients previously exposed to other anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> drugs including <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> (AA) </plain></SENT>
<SENT sid="1" pm="."><plain>Here we report on the occurrence of a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with <z:mp ids='MP_0004026'>monosomy</z:mp> 5 and/or 7 in two patients after 2CdA treatment, without or prior to other toxic exposure </plain></SENT>
<SENT sid="2" pm="."><plain>In light of a literature review and given the involvement of chromosomes frequently abnormal in secondary <z:mpath ids='MPATH_336'>leukaemias</z:mpath>, we suggest that 2CdA may induce <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
</text></document>